<DOC>
	<DOCNO>NCT02126982</DOCNO>
	<brief_summary>Clopidogrel besylate ( CB ) differentiate relative orignal clopidogrel hydrogen sulfate ( CHS ) pharmacokinetics antiplatelet potency healthy volunteer . In addition , CB exhibit similar pharmacodynamic property compare CHS patient history acute coronary syndrome ( ACS ) patient ACS undergo percutaneous coronary intervention ( PCI ) . However , lack data clinical efficacy safety salt original salt patient cardiovascular disease . The aim study investigate clinical efficacy safety CB relation CHS patient eligible receive clopidogrel .</brief_summary>
	<brief_title>Salts Clopidogrel : Investigation ENsure Clinical Equivalence</brief_title>
	<detailed_description>It well document platelet play important role pathogenesis acute coronary syndrome . This phenomenon significantly strengthen position antiplatelet drug treatment , prevention syndrome . In term administration , antiplatelet drug divide two category , oral intravenous medication . Of , oral medication choice long-term prophylactic treatment patient acute coronary syndrome . Among , clopidogrel , together aspirin cornerstone antiplatelet therapy . Indeed , clopidogrel widely use antiplatelet drug . It second sale worldwide atorvastatin prescribe 100 million patient worldwide . Clopidogrel use monotherapy combination aspirin . The efficacy reduce ischemic event patient ACS show 15 major clinical study involve 200,000 patient . These study also prove safety clopidogrel bleed complication ( 1-2 % per year ) .Clopidogrel second generation thienopyridine inhibits bind ADP purinergic receptor platelet membrane . The ADP activate platelet different receptor couple G-proteins . The main receptor platelet activation ADP P2Y12 , associate adenyl cyclase cause deactivation result reduction level c-AMP . The identification receptor lead complete elucidation mechanism action clopidogrel , prove irreversible antagonist P2Y12 . Clopidogrel prodrug , grant , absorbed intestine process important role play protein carrier ABCB1/MDR1 . Then clopidogrel convert liver pharmacologically active metabolite action cytochrome P450 ( CYP450 ) mainly isoform CYP2C19 isoforms CYP3A4 , CYP3A5 , CYP1A2 , CYP2B6 CYP2C9 . It note 85 % clopidogrel absorb , hydrolyze esterases intestinal mucosa blood form biologically inactive product 15 % administer drug convert active metabolite , potent , irreversible , selective inhibitor receptor P2Y12 ADP result inhibition activation receptor GPIIb / IIIa thereby prevent platelet aggregation . Currently , clopidogrel generic form available market . Indeed , 2010 10 year circulation original formulation ( clopidogrel bisulfate ) trade name Plavix Iscover , release new generic formulation clopidogrel ( generic ) due expiration period exclusive marketing use original formulation . Main difference generic form clopidogrel original formulation ( clopidogrel bisulfate ) pharmacochemical recommendation salt clopidogrel , case generic formulation benzenesulfonic ( besylate ) hydrochloride salt . Generic formulation clopidogrel receive marketing approval health authority European Union . Bioequivalence comparative study clopidogrel generic formulation healthy volunteer generic clopidogrel bisulfate , clopidogrel besylate clopidogrel hydrochloride proven pharmacodynamic pharmacokinetic profile . Considering wide variability platelet response clopidogrel treatment high incidence atherothrombotic event clopidogrel hyporesponsive patient , study compare pharmacodynamic property various generic clopidogrel formulation original clopidogrel bisulfate CAD patient essential . Therefore , give numerous generic clopidogrel salt commercially available today , importance note clinical data research result arise use formulation patient cardiovascular disease relate specific product use generally generic clopidogrel . Our group perform two prospective pharmacodynamic study compare antiplatelet effectiveness clopidogrel besylate clopidogrel bisulfate patient history ACS , ACS patient undergo PCI . In study show pharmacodynamic bioequivalence platelet function test perform . There strong need conduct clinical study adequate number patient clopidogrel generic formulation commercially available order confirm therapeutic equivalence innovator product .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Both sexes age &gt; 18 year age &lt; 85 year Patients ACS without percutaneous coronary intervention , stable CAD , history ischemic stroke/TIA , PAD , carotid artery disease atrial fibrillation agree study participation comply require study procedure &gt; 85 year &lt; 18 year Patients hypersensitivity reaction contraindication clopidogrel , active bleed history severe bleeding ( peptic ulcer , trauma intracranial hemorrhage ) , blood coagulation disorder , uncontrolled severe hypertension , history drug alcohol abuse , pregnancy breastfeeding , liver disease chronic kidney disease , malignancy , disagree study participation , evidence poor compliance require study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>clopidogrel besylate</keyword>
	<keyword>clopidogrel hydrogen sulfate</keyword>
	<keyword>Generic clopidogrel</keyword>
	<keyword>Coronary Artery Disease</keyword>
</DOC>